News Point MsiaSing's
Wednesday, May 3, 2017
INVIVOSCRIBE® RECEIVES FDA APPROVAL FOR THE LEUKOSTRAT® CDX FLT3 MUTATION ASSAY COMPANION DIAGNOSTIC TEST FOR THE SELECTION OF PATIENTS FOR RYDAPT® AND IS THE FIRST COMPANION DIAGNOSTIC FOR AML
INVIVOSCRIBE® RECEIVES FDA APPROVAL FOR THE LEUKOSTRAT® CDX FLT3 MUTATION ASSAY COMPANION DIAGNOSTIC TEST FOR THE SELECTION OF PATIENTS FOR RYDAPT® AND IS THE FIRST COMPANION DIAGNOSTIC FOR AML
No comments:
Post a Comment
‹
›
Home
View web version
No comments:
Post a Comment